Emergent Suspends COVID-19 Vaccine API Manufacturing As US FDA Inspects Bayview Plant
Executive Summary
After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.
You may also be interested in...
White House Touts Public Confidence In FDA Safety Decisions As It Aims To Expand Vaccinations
Public confidence in the Johnson & Johnson vaccine may be shaken. But faith in the regulatory system is solid, according to a recent poll, an Administration official maintained.
Emergent COVID-19 Vaccine Plant’s Quality Issues Draw Unusual Spotlight From US FDA Topsiders
Remediation must be quick and sure, say FDA’s Woodcock and Marks, despite challenges with facilities, equipment, processes and personnel training.
J&J COVID-19 Vaccine Rollout Resumes In EU With New Rare Blood Clot Warning
Similarities to AstraZeneca blood clots are clear, but more research needed before any ‘class effect’ conclusions can be drawn.